# A Study of ICP-192 in Patients With Advanced Solid Tumors

> **NCT04565275** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 45 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Urothelial Carcinoma
- Cholangiocarcinoma

## Interventions

- **DRUG:** Drug ICP-192

## Key facts

- **NCT ID:** NCT04565275
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-01
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-04-15
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04565275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04565275, "A Study of ICP-192 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04565275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*